论文部分内容阅读
目的探讨米非司酮治疗子宫内膜异位症(EMS)的临床疗效及其作用机制。方法选取南康市中医院2014年11月—2015年11月收治的EMS患者100例,按照治疗方式的不同分成对照组和试验组,各50例。对照组患者给予孕三烯酮胶囊治疗,试验组患者给予米非司酮片治疗,两组患者均持续治疗3个月。比较两组患者的临床疗效、治疗期间不良反应发生情况及治疗时间。结果试验组患者临床疗效优于对照组(P<0.05)。试验组患者不良反应发生率低于对照组(P<0.05)。试验组患者治疗时间短于对照组(P<0.05)。结论米非司酮治疗EMS临床疗效明确,可有效缩短治疗时间,且安全性好。
Objective To investigate the clinical efficacy and mechanism of mifepristone in the treatment of endometriosis (EMS). Methods 100 cases of EMS patients who were admitted from November 2014 to November 2015 in Nankang Hospital of Traditional Chinese Medicine were divided into control group and experimental group according to different treatment methods, 50 cases each. Patients in the control group were treated with gestrinone capsules. Patients in the test group were treated with mifepristone tablets. Both groups were treated for 3 months. The clinical efficacy of the two groups were compared, the incidence of adverse reactions and the duration of treatment during treatment. Results The clinical efficacy of the experimental group was better than that of the control group (P <0.05). The incidence of adverse reactions in the experimental group was lower than that in the control group (P <0.05). Treatment group patients shorter duration of treatment than the control group (P <0.05). Conclusion The efficacy of mifepristone in the treatment of EMS is clear, which can shorten the treatment time and have good safety.